LABP News and Press, Landos Biopharma Inc. From 06/08/21

The following slide deck was published by Landos Biopharma, Inc. in conjunction with this event. For further details see: Landos Biopharma (LABP) Investor Presentation - Slideshow

BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassag...

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreemen...

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board ...

Landos Biopharma (LABP): Q1 GAAP EPS of -$0.38 in-line.Cash, cash equivalents and marketable securities of $106.4MPress Release For further details see: Landos Biopharma EPS in-line

Landos Biopharma (LABP) and LianBio announce an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan and Macau) and select Asian markets.Omilancor is an ...

Completed initial public offering of common stock, raising approximately $100 million in gross proceeds Following positive Phase 2 results of omilancor in ulcerative colitis, including statistically significant immunological and biomarker results, end-of-Phase 2 Meeting with FDA...

BLACKSBURG, Va., and SHANGHAI, China and PRINCETON, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, and LianBio, a biotechn...

Company’s second omilancor program entering a Phase 2 study with plans to pursue at least five autoimmune indications Topline results are expected in the second quarter of 2022 BLACKSBURG, Va., May 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clin...

Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022 BLACKSBURG, Va., April 29, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (...